28 patents
Utility
PVRL2 And/or Pvrig As Biomarkers for Treatment
14 Dec 23
The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
Gad S. COJOCARU, Tal Fridman KFIR, Emmanuel WEYL, Amit NOVIK, Yossef KLIGER, Niv SABATH, Eran OPHIR, Zoya ALTEBER, Masha FRENKEL
Filed: 26 Oct 21
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations, Anti-tigit Antibodies, and ANTI-PD-1 Antibodies
16 Nov 23
The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
Filed: 30 Sep 21
Utility
PVRIG polypeptides and methods of treatment
24 Oct 23
The present invention is directed to PVRIG polypeptides and their uses.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
Filed: 28 Jan 20
Utility
Anti-PVRIG antibodies and methods of use
24 Oct 23
The present invention is directed to anti-PVRIG antibodies and methods of using same.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Filed: 17 Jun 20
Utility
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
18 Jul 23
Anti-PVRIG and anti-TIGIT antibodies are provided.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Filed: 17 Jun 20
Utility
ILDR2 antagonists and combinations thereof
23 May 23
The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
Filed: 28 Nov 18
Utility
Anti-PVRIG antibodies and methods of use
11 Apr 23
The present invention is directed to anti-PVRIG antibodies and methods of using same.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Filed: 21 Jan 20
Utility
Triple Combination Antibody Therapies
9 Mar 23
The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
Filed: 7 Dec 21
Utility
Anti-pvrig and Anti-tigit Antibodies for Enhanced Nk-cell Based Tumor Killing
23 Feb 23
Anti-PVRIG and anti-TIGIT for use in methods of treatment based on the enhanced NK-cell using the antibodies for the treatment of cancer.
Maya Kotturi, Sarah Whelan, Paul Neeson, Jessica Li, Joseph A. Trapani, Eran Ophir, Moran Galperin
Filed: 7 Dec 20
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations and ANTI-PD-1 Antibodies
1 Dec 22
The present invention is directed to combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry Adewoye, John Hunter, Anat Cohen-Dayag, Paul A. Basciano, Brian D. Lamon
Filed: 28 Jul 20
Utility
CorrectedPolypeptides and Uses Thereof for Treatment of Autoimmune Disorders and Infection
6 Oct 22
This invention relates to C10RF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
Filed: 18 Nov 20
Utility
Anti-pvrig Antibodies Formulations and Uses Thereof
8 Sep 22
The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof.
Mark WHITE, Adeboye Henry ADEWOYE, Michael BUCKLEY, Jun LU, John HUNTER, Anat COHEN DAYAG
Filed: 28 Jul 20
Utility
Combinations of ANTI-ILDR2 Antibodies and PD-1 Antagonists
2 Jun 22
The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer.
Lars RÖSE, Uwe GRITZAN, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
Filed: 6 Apr 20
Utility
Polypeptides and Polynucleotides, and Uses Thereof for Treatment of Immune Related Disorders and Cancer
17 Feb 22
This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development.
Amir TOPORIK, Amit NOVIK, Ronen SHEMESH
Filed: 18 May 21
Utility
Triple combination antibody therapies
18 Jan 22
The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
Filed: 1 Jun 18
Utility
Anti-PVRIG antibodies and methods of use
11 Jan 22
The present invention is directed to anti-PVRIG antibodies and methods of using same.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Filed: 27 Sep 16
Utility
Polypeptides and Uses Thereof for Treatment of Autoimmune Disorders and Infection
19 Aug 21
This invention relates to C10RF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
Filed: 18 Nov 20
Utility
Anti-pvrig Antibodies and Methods of Use
24 Jun 21
The present invention is directed to anti-PVRIG antibodies and methods of using same.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
Filed: 17 Jun 20
Utility
Anti-tigit Antibodies, Anti-pvrig Antibodies and Combinations Thereof
6 Jan 21
Anti-PVRIG and anti-TIGIT antibodies are provided.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
Filed: 16 Jun 20
Utility
Pvrig Polypeptides and Methods of Treatment
9 Dec 20
The present invention is directed to PVRIG polypeptides and their uses.
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
Filed: 27 Jan 20